Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced NSCLC and PD-L1 =50%: A Systematic Review and Meta-Analysis

Category Systematic review
Conference2025 World Conference on Lung Cancer
Year 2025
This article has no abstract
Epistemonikos ID: adb1bdc994872519b449dcbf9156e9724783a04f
First added on: Mar 25, 2026